Literature DB >> 2738100

Role of mevalonic acid in the regulation of natural killer cell cytotoxicity.

J L Cutts1, T J Scallen, J Watson, A D Bankhurst.   

Abstract

Considerable evidence has accumulated for a role of a nonsteroidal mevalonate product in the regulation of DNA replication and cell division. We report here a similar requirement for mevalonate in a nonreplicative function, that of natural killer (NK) cell cytotoxicity. Treatment of NK cells with 10 microM compactin for 48 hr results in a significant inhibition of cytotoxicity which can be completely reversed by treatment with 1 mM mevalonate, but not cholesterol, dolichol, or isopentenyl adenine. Protein and RNA synthesis appear to be involved in this reversal. Treatment with compactin and reversal with mevalonate do not affect the phenotypic distribution of the effector cell population, and the cell type involved in the inhibition and reversal of cytotoxicity is a CD16 (Leu 11)-, Leu 19-positive, large granular lymphocyte. The conjugation of the target and effector cell early in the lytic pathway is inhibited by compactin treatment of the effector cell population, and this inhibition is reversed by mevalonate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2738100     DOI: 10.1002/jcp.1041390314

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  11 in total

1.  Quantitative assay for morphogenesis indicates the role of extracellular matrix components and G proteins.

Authors:  R J Klebe; T M Overfelt; V L Magnuson; B Steffensen; D L Chen; G Zardeneta
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

2.  The effects of atorvastatin in experimental autoimmune uveitis.

Authors:  P B Thomas; T Albini; R K Giri; R F See; M Evans; N A Rao
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

3.  Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.

Authors:  Oliver Neuhaus; Olaf Stüve; Scott S Zamvil; Hans-Peter Hartung
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  The challenge of rejection and cardiac allograft vasculopathy.

Authors:  W G Cotts; M R Johnson
Journal:  Heart Fail Rev       Date:  2001-09       Impact factor: 4.214

Review 5.  Perspectives on cardiac allograft vasculopathy.

Authors:  J B Young
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

6.  Effects of lovastatin on natural killer cell function and other immunological parameters in man.

Authors:  R McPherson; C Tsoukas; M G Baines; A Vost; M R Melino; R V Zupkis; H F Pross
Journal:  J Clin Immunol       Date:  1993-11       Impact factor: 8.317

7.  Blockade of mevalonate production by lovastatin attenuates bombesin and vasopressin potentiation of nutrient-induced insulin secretion in HIT-T15 cells. Probable involvement of small GTP-binding proteins.

Authors:  G Li; R Regazzi; E Roche; C B Wollheim
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

8.  Lovastatin inhibits proliferation of rat mesangial cells.

Authors:  M P O'Donnell; B L Kasiske; Y Kim; D Atluru; W F Keane
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  Isoprenoid metabolism is required for stimulation of the respiratory burst oxidase of HL-60 cells.

Authors:  G M Bokoch; V Prossnitz
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

Review 10.  Graft vessel disease following heart transplantation: a systematic review of the role of statin therapy.

Authors:  Robin Som; Peter J Morris; Simon R Knight
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.